Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.63 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.48 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.48 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4516652 | 0.91 | ESR1 (0.71) | ESR1ESR2ABCC1 | |
| SCHEMBL4512329 | 0.85 | ESR1 (0.66) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL4518053 | 0.85 | ESR1 (0.61) | ESR1ESR2 | |
| SCHEMBL4510110 | 0.78 | ESR1 (1.00) | ESR1ESR2ABCC1 | |
| SCHEMBL3113722 | 0.77 | ESR1 (0.65) | ESR1ESR2 | |
| Trifluoroacetic Acid SCHEMBL4518991 | 0.77 | ESR1 (0.72) | ESR1ESR2ENPP3ENPP1 | |
| Hydrochloric Acid SCHEMBL4513519 | 0.77 | ESR1 (0.98) | ESR1ESR2ABCC1 | |
| SCHEMBL11182993 | 0.77 | ESR1 (0.74) | ESR1ESR2 | |
| Oxalic Acid SCHEMBL7456866 | 0.76 | ESR1 (0.80) | ESR1ESR2ENPP3ENPP1 | |
| SCHEMBL7980102 | 0.76 | ESR1 (0.69) | ESR1ESR2ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585977-B2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELI LILLY AND COMPANY (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | DALLY ROBERT DEAN | 2008-09-04 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214612-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | GPER1, ESR2, ESR1 | ESR1 3/4885ESR2 2/4885ENPP3 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.